| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $428,778 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Choo Chee Kong | 3 | $428,778 | 0 | $0 | $428,778 |
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is …
Over the last 12 months, insiders at CytoMed Therapeutics Limited have bought $428,778 and sold $0 worth of CytoMed Therapeutics Limited stock.
On average, over the past 5 years, insiders at CytoMed Therapeutics Limited have bought $428,778 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Choo Chee Kong () — $428,778.
The last purchase of 100,000 shares for transaction amount of $150,000 was made by Choo Chee Kong () on 2026‑07‑20.
| 2026-07-20 | Choo Chee Kong | 100,000 1.2935% | $1.50 | $150,000 | -7.57% | |||
| 2026-07-14 | Choo Chee Kong | 100,000 1.2428% | $1.50 | $150,000 | -10.88% | |||
| 2026-05-13 | Choo Chee Kong | 112,000 1.4415% | $1.15 | $128,778 | +24.15% |
| Increased Positions | 4 | +100% | 52,063 | +287.26% |
| Decreased Positions | 2 | -50% | 17,059 | -94.12% |
| New Positions | 4 | New | 52,063 | New |
| Sold Out Positions | <1 | Sold Out | 4,835 | Sold Out |
| Total Postitions | 6 | +50% | 53,128 | +193.14% |